Live Feeds
● LIVE Updated 1h ago · 17 sources tracked

New Drug Approved by F.D.A. for Pancreatic Cancer Could Be First of Many

The FDA has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval coincides with a broader shift toward personalized cancer treatment, highlighted by a breakthrough from Moderna and Merck. Their personalized mRNA cancer vaccine successfully prevented melanoma recurrence in late-stage trials. Experts describe these developments as the start of an era where vaccines and targeted inhibitors train the immune system to fight a specific patient's cancer, offering new options for diseases traditionally considered deadly.

RSS Source map (17)

What changed

Moderna and Merck have developed a personalized mRNA vaccine that prevents melanoma recurrence in late-stage trials.

Live updates

  1. FDA-Approved Pancreatic Cancer Drug Joins New Wave of Personalized Oncology

    The FDA has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval coincides with a broader shift toward personalized cancer treatment, highlighted by a breakthrough from Moderna and Merck. Their personalized mRNA cancer vaccine successfully prevented melanoma recurrence in late-stage trials. Experts describe these developments as the start of an era where vaccines and targeted inhibitors train the immune system to fight a specific patient's cancer, offering new options for diseases traditionally considered deadly.

    Why it matters

    Pancreatic adenocarcinoma is notoriously difficult to treat and often fatal. The introduction of daraxonrasib provides a new chemical approach to inhibition, while mRNA technology introduces a custom-made immunological approach. Together, these represent a transition from general chemotherapy to patient-specific precision medicine.

    What is confirmed

    • The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma.
    • Moderna and Merck developed a personalized mRNA cancer vaccine that prevents melanoma recurrence in late-stage trials.

    What to watch next

    • Clinical trial results for mRNA vaccines targeting pancreatic cancer
    • Long-term survival data for patients using daraxonrasib
    Sources used for this update (9)
    1. www.straitstimes.com — Success after a century of failures: Inside Moderna and Merck’s cancer vaccine breakthrough
    2. journalstar.com — Dolly Parton’s immortal music legacy in 10 essential songs
    3. jen.jiji.com — Germany, knife attack at Rosenheim station: 31-year-old British woman killed
    4. jen.jiji.com — US Open, Paolini - Erjavec in the first round: live match
    5. tucson.com — Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
    6. journalstar.com — DC’s interstellar peacekeepers have landed in Nebraska — here’s where and why
    7. jen.jiji.com — Nepal authorities, ‘risk of new floods, at least 800 dead and over 3,000 missing’
    8. jen.jiji.com — Ranucci Case, Report journalists' assembly: "State of agitation, we will strike if necessary"
    9. www.applevalleynewsnow.com — Week in review: Test your knowledge of notable news
    confidence 100%

  2. FDA Approves New Drug for Pancreatic Cancer

    The US FDA has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval marks a new approach to treating the disease, which is notoriously deadly. Some patients, including former University of Florida President Sasse, have already received the medication, crediting it with extending their life.

    Why it matters

    Pancreatic cancer has limited treatment options and poor survival rates. The approval of daraxonrasib offers hope for improved treatment outcomes. This development is part of a larger effort to develop effective treatments for pancreatic cancer.

    What is confirmed

    • The FDA approved a pill from Revolution Medicines to treat pancreatic cancer.
    • The approved drug is designed to improve survival rates for pancreatic cancer.
    • Some patients at Dartmouth are among the first to receive the medication.
    • Former University of Florida President Sasse credited the drug with extending his life.
    • The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

    What to watch next

    • Further clinical trials to confirm the efficacy of daraxonrasib
    • Development of similar medicines by other pharmaceutical companies
    • Long-term effects of daraxonrasib on patients with pancreatic cancer
    Sources used for this update (7)
    1. medicalxpress.com — FDA approval opens new chapter in pancreatic cancer treatment
    2. jen.jiji.com — Report, Presutti and Piervincenzi to host. Three relocation proposals for Ranucci
    3. jen.jiji.com — Roller coaster at Six Flags park in California closes: "Linked to brain injuries, coma, and deaths"
    4. journalrecord.com — After a century of failures, cancer vaccine hits major milestone
    5. jen.jiji.com — Ukraine, Russian raid against warehouse near Kyiv causes massacre: at least 27 dead
    6. www.news-medical.net — FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
    7. jen.jiji.com — Return migration, Codacons: "Chaos between construction sites and expensive fuel, odyssey for motorists"
    confidence 90%

  3. FDA Approves First-of-a-Kind Pancreatic Cancer Pill from Revolution Medicines

    The Food and Drug Administration approved a first-of-a-kind pill from Revolution Medicines on Wednesday to treat pancreatic cancer. The drug is designed to improve survival rates for a disease noted for being notoriously deadly. Some patients at Dartmouth are among the first to receive the medication. Former University of Florida President Sasse credited the drug with extending his life. This approval marks a new approach to treating the disease and has sparked a race to develop similar medicines.

    Why it matters

    Pancreatic cancer is traditionally difficult to treat with high mortality rates. This approval introduces a new class of medication that experts believe will transform standard care. The development positions Revolution Medicines as a potential major player in oncology.

    What is confirmed

    • The FDA approved a new drug for pancreatic cancer on Wednesday.
    • Revolution Medicines developed the first-of-a-kind pill for the disease.
    • The drug is intended to improve survival for patients with pancreatic cancer.

    Still unconfirmed

    • The drug is named Rasonque.
    • Revolution Medicines could become the next oncology titan.

    What to watch next

    • FDA approval of subsequent medicines following this new treatment model.
    Sources used for this update (10)
    1. WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
    2. The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
    3. The New York Times — The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
    4. WMUR — Dartmouth patients among first to get new drug that fights pancreatic cancer
    5. www.forbes.com — Forbes Daily: Nvidia Beats Expectations As Data Center Business Grows
    6. BioSpace — RevMed could become ‘next oncology titan’ with Rasonque nod
    7. www.today.com — FDA Approves ‘Game-Changing’ Pancreatic Cancer Drug
    8. www.statnews.com — Decoding DEA action on kratom-related substances
    9. www.usatoday.com — FDA approves pancreatic cancer drug Sasse credits with extending his life
    10. www.kpbs.org — FDA approves landmark pancreatic cancer drug that's shown to improve survival
    confidence 90%